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Diana E. Ayala1
1Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC); University of Vigo, Vigo, Spain;
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This commentary refers to ‘Asleep blood pressure: signifi-
cant prognostic marker of vascular risk and therapeutic tar-
get for prevention’, by R.C. Hermida et al., 39:4159–4171.
The commentary by Torp-Pedersen et al., challenging our conclusion
concerning the prognostic merit of asleep blood pressure (BP) as the
most relevant BP-derived marker of cardiovascular disease (CVD)
risk,1 contains several arguable statements:
(1) We not only conducted Cox-survival but also discriminative/predict-
ive analyses of BP parameters by C-statistic and Akaike Information
Criterion methods. Results document asleep systolic BP (SBP)
mean provide significantly better CVD-outcome prediction than of-
fice SBP and that adding office or awake SBP to the model already
including asleep SBP mean fails to improve prediction.1
(2) The argument by Top-Pedersen et al. for exclusive use of the C-
statistic for model selection is not supported by Hlatky et al.,2 who
specifically state: ‘The C-index does not test whether the risk pre-
dictions are accurate or whether the risk model is well calibrated. . .
is relatively insensitive to change, and may not increase appreciably
even when a new marker is statistically significant and independently
associated with risk’.
(3) The C-statistic, frequently used in diagnostic testing, is suboptimal
for assessing models that predict risk.1–3 As an illustrative ex-
ample of Cook’s impecable contentions,3 the C-statistic for the
model including all significant confounders documented in our
study1 plus asleep SBP mean and sleep-time relative SBP decline
is 0.812 95%CI (0.801–0.823). Removing diabetes or sex yields
C-statistics of 0.812 (0.800–0.823) and 0.807 (0.795–0.819),
respectively, mistakenly suggesting neither diabetes nor sex is
‘predictive’ of CVD-outcome despite their well-recognized rele-
vance as CVD risk markers.
(4) Torp-Pedersen et al. do not seem to properly describe our findings
by refering to an external environmental marker, i.e., ‘night-time’ BP
rather than the internal biological marker of ‘sleep-time’ BP that is
our specific focus. Endogenous circadian rhythms in neuroendo-
crine, endothelial, vasoactive peptide, opioid, and haemodynamic
parameters—including renin, angiotensin, and aldosterone—that
are mechanisms of the circadian BP variation are all synchronized by
the rest/activity, not the day/night, cycle. As already discussed,1 reli-
ance on arbitrary and fixed clock-hours not fully representative of
the individualized rest/activity pattern to calculate ‘daytime/night-
time’ BP means plus exclusive dependence on the C-statistic might
be among the potential limitations of the reported findings by Torp-
Pedersen et al.
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